Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
  • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
  • C07D295/182—Radicals derived from carboxylic acids
  • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
  • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Definitions

• the present invention relates to a stereoselective process for the preparation of (-)- halofenate (4-Chloro- ⁇ -(3-trifluoromethylphenoxy)phenylacetic acid) and intermediates thereof.
• esters and amides derivatives of (-)-4-Chloro- ⁇ -(3- trifluoromethylphenoxy)phenylacetic acid are chiral compounds and are useful in ameliorating a variety of physiological conditions, including conditions associated with blood lipid deposition, Type II diabetes and hyperlipidema ⁇ see, e.g., U.S. Patent Application No. 10/656,567 and U.S. Patent No. 6,262,118 which are incorporated herein by reference in their entirety).
• Halofenic acid contains a single chiral center at an asymmetrically substituted carbon atom alpha to the carbonyl carbon atom, and therefore exist in two enantiomeric forms.
• the (-)-enantiomer of halofenic acid is about twenty-fold less active in its ability to inhibit cytochrome P450 2C9 compared to the (+)-enantiomer.
• Administration of a racemic halofenic acid or its derivatives can lead to a variety of drug interaction problems with other drugs, including anticoagulants, antiinflammatory agents and other drugs, that are metabolized by this enzyme.
• enantiomerially enriched forms of ⁇ -(phenoxy)phenylacetic acids or its derivatives are valuable chemical intermediates for the preparation of pharmaceutical compounds.
• the present invention provides methods that can be used to reliably convert substituted phenylacetic acids to corresponding ⁇ -(substituted)phenylacetic acid derivatives in high yields and in high enantiomeric purity.
• the present invention provides a method for producing a compound of formula (I):
• R 1 is a member selected from the group consisting of:
• each R 2 is a member independently selected from the group consisting Of(C 1 - C 4 )alkyl, halo, (Q-G ⁇ haloalkyl, amino, (C 1 -C 4 )aminoalkyl, amido, (CrC ⁇ amidoalkyl, (C 1 - C 4 )sulfonylalkyl, (Q-C ⁇ sulfamylalkyl, (Q-G ⁇ alkoxy, (C 1 -C 4 )heteroalkyl, carboxy and nitro; the subscript n is 1 when R 1 has the formula (a) or (b) and 2 when R 1 has the formula (c) or (d); the subscript m is an integer of from 0 to 3;
• step (b) brominating the product of step (a) with bromine in a compatible solvent
• step (c) esterifying the product of step (b) with a chiral alcohol selected from the group consisting of:
• the present invention provides ⁇ -(substituted)phenylacetic acid compounds of the formula (IV):
• R 1 is a member selected from the group consisting of:
• n 1 when R 1 has the formula (a) or (b) and 2 when R 1 has the formula (c) or (d);
• Alkyl refers to straight or branched aliphatic hydrocarbons chain groups of one to ten carbon atoms, preferably one to six carbon atoms, and more preferably one to four carbon atoms.
• Exemplary alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 2-propyl, tert-butyl, pentyl, and the like.
• Aryl refers to a monovalent monocyclic or bicyclic aromatic hydrocarbon moiety of 6 to 10 carbon ring atoms. Unless stated or indicated otherwise, an aryl group can be substituted with one or more substituents, preferably one, two, or three substituents, and more preferably one or two substituents selected from alkyl, haloalkyl, nitro, and halo! More specifically the term aryl includes, but is not limited to, phenyl, 1-naphthyl, and 2-naphthyl, and the like, each of which is optionally substituted with one or more substituent(s) discussed above.
• Chiral or “chiral center” refers to a carbon atom having four different substituents. However, the ultimate criterion of chirality is non-superimposability of mirror images.
• Enantiomeric mixture means a chiral compound having a mixture of enantiomers, including a racemic mixture.
• enantiomeric mixture refers to a chiral compound having a substantially equal amounts of each enantiomers. More preferably, enantiomeric mixture refers to a racemic mixture where each enantiomer is present in an equal amount.
• Enantiomerically enriched refers to a composition where one enantiomer is present in a higher amount than prior to being subjected to a separation process.
• halide and “halo” are used interchangeably herein and refer to halogen, which includes F, Cl, Br, and I, as well as pseudohalides, such as -CN and -SCN.
• Haloalkyl refers to alkyl group as defined herein in which one or more hydrogen atoms have been replaced with halogens, including perhaloalkyls, such as trifluoromethyl.
• Halofenate refers to 2-acetamidoethyl 4-chlorophenyl-(3-trifluoromethyl- phenoxy)acetate (i.e., 4-chloro- ⁇ -(3-(trifluoromethyl)phenoxy)benzeneacetic acid, 2- (acetylamino)ethyl ester or (4-chlorophenyl)(3-trifluoromethylphenoxy)acetic acid), 2- (acetylamino)ethyl ester).
• Heteroalkyl means a branched or unbranched acyclic saturated alkyl moiety containing one or more heteroatoms or one or more heteroatom-containing substituents, where the heteroatom is O, N, or S.
• Each of R a and R b is independently hydrogen, alkyl, haloalkyl, aryl, or aralkyl.
• Optical purity refers to the amount of a particular enantiomer present in the composition. For example, if a composition comprises 98% of the first enantiomer and 2% of the second enantiomer, the optical purity of the first enantiomer is 98%.
• phenyl refers to an optionally substituted phenyl group. Suitable phenyl substituents are same as those described in the definition of "aryl.”
• phenoxy refers to a moiety of the formula -O Ar a , wherein Ar a is phenyl as defined herein.
• ⁇ -(phenoxy)phenylacetic acid refers to acetic acid that is substituted on the 2-position with an optionally substituted phenyl and optionally substituted phenoxy moieties.
• Protecting group refers to a moiety that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et al., Compendium of Synthetic Organic Methods, VoIs. 1-8 (John Wiley and Sons, 1971-1996), which are incorporated herein by reference in their entirety.
• Representative hydroxy protecting groups include acyl groups, benzyl and trityl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.
• Representative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), fe/t-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2- trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9- fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like.
• rate when referring to a formation of a reaction product refers to kinetic and/or thermodynamic rates.
• the term "treating”, “contacting” or “reacting” refers to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
• compositions contain a substantially greater proportion of the (-)-isomer in relation to the (+)-isomer.
• the term “substantially free of its (+) stereoisomer” means that the composition is at least 90% by weight of the (-)-isomer and 10% by weight or less of the (+)-isomer.
• the term "substantially free of its (+)-stereoisomer” means that the composition contains at least 99% by weight of the (-)-isomer and 1% by weight or less of the (+)-isomer. In the most preferred embodiment, the term “substantially free of its (+)- stereoisomer” means that the composition contains greater than 99% by weight of the (-)- isomer. These percentages are based upon the total amount of isomers in the composition.
• the present invention provides a method for synthesizing a ⁇ -(halo) ⁇ henylacetic acid chiral ester derivative.
• the chiral ester on the ⁇ -(halo)phenylacetic acid directs the alkylation of 3-trifluoromethylphenol to stereoselectively produce ⁇ -(phenoxy)phenylacetic acid derivatives.
• compounds produced using methods of the present invention are useful in producing ⁇ -(phenoxy)phenylacetic acid derivatives such as those disclosed in U.S. Patent Application No. 10/656,567 and U.S. Patent No. 6,262,118 in high yields.
• compounds and methods of the present invention are useful in producing (-)- halofenate.
• methods of the present invention are based on the surprising and unexpected discovery by the present inventors that substitutedphenylacetic acids can be activated, brominated with bromine and esterified to result in a chiral ⁇ -halophenyl acetic ester intermediate in high yield.
• This intermediate can then be used to stereoselectively produce ⁇ - (phenoxy)phenylacetic acid derivatives.
• methods of the present invention provide a desired enantiomer of a ⁇ -(phenoxy)phenylacetic acid derivative in yields of at least about 40%, preferably at least about 50%, more preferably at least about 60%, and most preferably at least about 70%.
• methods of the present invention provide a desired enantiomer of the ⁇ -(phenoxy)phenylacetic acid compound in optical purity of at least about 90%, preferably at least about 95%, more preferably at least about 97%, and most preferably at least about 98%.
• phenylacetic acid x can be converted to an activated carboxylic acid derivative and subsequently halogenated with molecular bromine to give ⁇ - bromophenylacetyl halide xi in two steps.
• the phenyl acetic acid is preferably a halophenylacetic acid, more preferably 4-halo-phenylacetic acid and more preferably 4- chloro-phenylacetic acid.
• carboxylic activating agents suitable for use in the present invention include, but are not limited to thionyl halides such as thionyl chloride (SOCl 2 ); anhydrides, such as trifluoroacetic anhydride (TFAA), and thioester generating reagents.
• the carboxylic acid activating agent is preferably a thionyl halide and more preferably thionyl chloride. It is commercially available as a clear liquid and may be used neat or in a compatible solvent.
• the acid halide is then converted to chiral ester xiii, where R 1 is a chiral alcohol auxiliary.
• R 1 is a chiral alcohol auxiliary.
• a wide variety of chiral auxiliaries can be used, including those disclosed in the Examples section below.
• the chiral auxiliary used results in making only one diasteromer of ⁇ -(phenoxy)phenylacetic acid.
• the chiral alcohol auxiliary compound itself should be of a sufficient enantiomeric purity in order to yield a highly enantiomerically enriched ⁇ -(phenoxy)phenylacetic acid derivative. In this manner, one enantiomer at the ⁇ -position is readily made, for example, by removing the chiral auxiliary.
• the chiral auxiliary is an chiral alcohol compound of the formula:
• the chiral alcohol has the formula:
• hydrolysis of the ⁇ -(phenoxy)phenylacetic acid ester xiii affords ⁇ - (phenoxy)phenylacetic acid xiv.
• hydrolyzing agents include, but are not limited to hydroxide, such as lithium hydroxide, potassium hydroxide, sodium hydroxide and the like; hydroperoxide, such as lithium hydroperoxide, potassium hydroperoxide, sodium hydroperoxoide and the like; and the like.
• 4-chlorophenylacetic acid 1 can be treated with thionyl chloride to activate the carboxylic acid. This can then be treated with bromine to form 4-chlorophenylacetyl chloride.
• the esterification is conveniently carried out with (S)-N 5 N- tetramethylenelactamide 2. This reaction sequence is particularly advantageous as the reactions are conveniently carried out in one reaction vessel with only one isolation step.
• the displacement reaction of ester 3 with 3-trifluoromethylphenol 4 in the presence of potassium hydroxide gives ⁇ -(phenoxy)phenylacetic acid ester 5. Hydrolysis of the ⁇ - (phenoxy)phenylacetic acid ester 5 with lithium hydroxide afforded ⁇ -(phenoxy)phenylacetic acid 6.
• (4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetic acid i.e., CPTA, can be prepared in five steps in about 73% yield following crystallization from heptane.
• the present invention provides a method of producing a compound of formula (I):
• R 1 is a member selected from the group consisting of:
• each R 2 is a member independently selected from the group consisting Of(C 1 - C 4 )alkyl, halo, (d-C ⁇ haloalkyl, amino, (CrC ⁇ aminoalkyl, amido, (CrC ⁇ amidoalkyl, (C 1 - C 4 )sulfonylalkyl, (Ci-C 4 )sulfamylalkyl, (d-C 4 )alkoxy, (CrC ⁇ heteroalkyl, carboxy and nitro; the subscript n is 1 when R 1 has the formula (a) or (b) and 2 when R 1 has the formula (c) or (d); the subscript m is an integer of from O to 3;
• the method generally involves:
• step (b) brominating the product of step (a) with bromine in a compatible solvent
• step (c) esterifying the product of step (b) with a chiral alcohol selected from the group consisting of:
• the brominating agent used in the preparation of the ⁇ -(phenoxy)phenylacetic acid has a significant effect on ease of isolation and overall yield of the process. For example, when bromine is used in the process of making the ⁇ - (phenoxy)phenylacetic acid compound, higher overall yields are obtained than by using other halogenating agents.
• the amount of halogenating agent used is not particularly important. The amount used is typically more than 1.00 molar equivalent, preferably about 1.5 molar equivalent or more, more preferably about 1.55 molar equivalent.
• the reactions are typically conducted in an compatible solvent.
• a compatible solvent is one which is inert to the reaction condtions and can readily dissolve the reactants.
• Suitable solvents for the above reactions are known by those of skill in the art.
• suitable solvents for the carboxylic acid activation, bromination, and esterification reactions include, but are not limited to, aprotic solvents, such as halogenated alkanes, tetrahydrofuran, aromatic hydrocarbons, dialkylethers, and mixtures thereof.
• a particularly preferred solvent is a halogenated alkane, more preferably 1, 2-dichloroethane.
• the bromination process involves heating the reaction mixture to a temperature in the range of from about 70 0 C to the boiling point of the solution, preferably from about 80 0 C to about 85 0 C. Heating is carried out until the reaction is complete, which typically ranges from about 1 to about 24 hours, preferably from about 2 to about 18 hours. At lower temperatures, longer reaction times may be needed. It will be readily apparent to those of skill in the art that the progress of this and other reactions in the method of the present invention can be monitored by, for example, HPLC, and the reaction deemed complete when the amount of unreacted starting reagents is less than about 1%.
• the bromine can be removed prior to addition of the chiral alcohol auxiliary. This can be done by connecting the reaction vessel to a vacuum pump and removing the bromine under reduced pressure. The pressure, rate and degree of removal is not particularly important.
• the solution can be cooled prior to and/or after the chiral alcohol auxiliary is added. This allows for the exothermic nature of the esterification reaction.
• the rate and amount of cooling of the reaction solution is not particularly important, hi one embodiment, the esterification reaction involves cooling the reaction mixture to a temperature in the range of from about 0 0 C to room temperature. The reaction is carried out until complete, which typically ranges from about 5 to about 60 minutes, typically about 30 minutes.
• this method can be done in one reaction vessel. In another embodiment, only the final product, the compound of formula (I), is isolated.
• methods of the present invention are directed to intermediates in the synthesis of ⁇ -(phenoxy)phenylacetic acids of formula (V):
• methods of the present invention are directed to the synthesis of ⁇ -( ⁇ henoxy)phenylacetic acid of Formula I or, preferably of Formula V, where R 2 is chloro.
• methods of the present invention are directed to the resolution of ⁇ -(phenoxy)phenylacetic acid of Formula I or, preferably, Formula V, where R 3 is preferably trifluoromethyl.
• the methods are directed to the stereoselective synthesis of compounds of Formula V wherein R 2 is Cl and R 3 is CF 3 e.g. halofenic acid.
• R 1 is a member selected from the group consisting of:
• n 1 when R 1 has the formula (a) or (b) and 2 when R 1 has the formula (c) or (d);
• R 1 is a member selected from the group consisting of:
• n 1 when R 1 has the formula (a) or (b) and 2 when R 1 has the formula (c) or (d);
• methods of the present invention provide at least about 50% yield of the desired enantiomer, preferably at least about 60%, more preferably at least about 70%, and most preferably at least about 75%.
• the compound is selected from the group consisting of:
• the compound is selected from the group consisting of:
• the method of the present invention essentially provides a compound enriched in the (-)-enantiomer based on the enantiomeric enrichment of the chiral auxiliary and the stereoselectivity of the reaction.
• Use of the (+)-enantiomer can be readily accomplished by use of the opposite enantiomer of the chiral alcohol auxiliary.
• the (+)-enantiomer can be made using (R)-N 5 N- tetramethylenelactamide.
• Enantiomerically pure ⁇ -(phenoxy)phenylacetic acid compounds are useful intermediates in preparing a variety of pharmaceutically active compounds, including ⁇ - (phenoxy)phenylacetic acid compounds disclosed in U.S. Patent Application No. 10/656,567 and U.S. Patent No. 6,262,118.
• another aspect of the present invention provides a method for enantioselectively producing a ⁇ -(phenoxy)phenylacetate compound of the formula:
• ⁇ -(phenoxy)phenylacetic acid compound Formula V wherein R 3 is alkyl or haloalkyl, R 2 is halo and R 7 is heteroalkyl, preferably N-acetyl 2-aminoethyl (i.e., a moiety of the formula -CH 2 CH 2 NHC( ⁇ O)CH 3 ).
• the method involves stereoselectively synthesizing a ⁇ - (phenoxy)phenylacetic acid compound of Formula V as described above and reacting the enantiomerically enriched ⁇ -(phenoxy)phenylacetic acid with a carboxylic acid activating reagent.
• Suitable carboxylic acid activating reagents include thionyl halides (e.g., thionyl chloride), anhydrides (e.g. TFAA), thioester generating reagents, and other carboxylic acid activating reagents known to one skilled in the art.
• the activated ⁇ -(phenoxy)phenylacetic acid is than reacted with a compound of the formula (R 7 -O) W M, e.g., N-acetyl ethanolamine derivative, to produce enantiomerically enriched ⁇ -(phenoxy)phenylacetate compound of Formula VI, where R 7 is as defined above, M is hydrogen or a metal, e.g., Na, K, Li, Ca, Mg, Cs, etc. and the superscript w is the oxidation state of M.
• R 7 is as defined above
• M is hydrogen or a metal, e.g., Na, K, Li, Ca, Mg, Cs, etc. and the superscript w is the oxidation state of M.
• the present inventors have discovered that the reaction between the activated acid and the compound of formula (R 7 -O) W M can be carried out without any significant racemization.
• reagents and solvents were purchased from Aldrich Chemical or Fisher Scientific. Operations were conducted under a positive nitrogen atmosphere. A Camile process control computer attached to a recirculating heating and cooling system was used to regulate jacket temperatures in the jacketed straight-walled bottom-drain glass reactors. Unless otherwise indicated, solvents were removed using a Buchi rotary evaporator at 15 to 25 torr with a bath temperature of up to 40 0 C. Solid samples were dried in a vacuum oven at 40 0 C, 15 to 25 torr. A Cenco HYVAC vacuum pump was used to supply vacuum of less than 1 torr for vacuum distillations.
• esters such as halofenate
• acetonitrile was used as the injection solvent.
• product concentrations for halofenate were evaluated by HPLC assay using the external standard method and the achiral analysis procedure at sample concentrations of less than 2.5 mg/mL.
• Example 1 Synthesis of a chiral alcohol auxiliary.
• reaction mixture was quenched with water (100 mL), and the organic layer was separated and washed with 100 mL of 10% Na 2 S 2 O 3 and then with saturated NaHCO 3 (100 mL). The organic layer was dried over Na 2 SO 4 and then concentrated in vacuo to give 45.8 g of crude product as a brown oil which was used in the next step without further purification.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (15)

Applications Claiming Priority (4)

Publications (1)

Family

ID=37894903

Family Applications (1)

Country Status (18)

Cited By (1)

Families Citing this family (5)

Citations (1)

Family Cites Families (69)

• 2006
  • 2006-09-20 US US11/525,200 patent/US7714131B2/en not_active Expired - Fee Related
  • 2006-09-21 PL PL06815150T patent/PL1940387T3/pl unknown
  • 2006-09-21 EP EP06815150A patent/EP1940387B1/en active Active
  • 2006-09-21 ES ES06815150T patent/ES2394973T3/es active Active
  • 2006-09-21 EA EA200800884A patent/EA015673B1/ru not_active IP Right Cessation
  • 2006-09-21 SI SI200631502T patent/SI1940387T1/sl unknown
  • 2006-09-21 JP JP2008532404A patent/JP2009515817A/ja not_active Withdrawn
  • 2006-09-21 BR BRPI0616188-0A patent/BRPI0616188A2/pt not_active IP Right Cessation
  • 2006-09-21 AU AU2006294950A patent/AU2006294950A1/en not_active Abandoned
  • 2006-09-21 RS RS20130001A patent/RS52608B/en unknown
  • 2006-09-21 WO PCT/US2006/036928 patent/WO2007038243A1/en active Application Filing
  • 2006-09-21 KR KR1020087009709A patent/KR101309605B1/ko not_active IP Right Cessation
  • 2006-09-21 DK DK06815150.5T patent/DK1940387T3/da active
  • 2006-09-21 PT PT68151505T patent/PT1940387E/pt unknown
  • 2006-09-21 CA CA2623350A patent/CA2623350C/en not_active Expired - Fee Related
• 2008
  • 2008-03-20 IL IL190325A patent/IL190325A/en not_active IP Right Cessation
  • 2008-12-29 HK HK08114045.8A patent/HK1119953A1/xx not_active IP Right Cessation
• 2013
  • 2013-01-02 HR HRP20130001TT patent/HRP20130001T1/hr unknown

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events